Structurally and functionally altered transcription factors have been associated with many human neoplasms. A better understanding of these transcriptional defects has revealed new therapeutic opportunities.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Bob Crimi
References
Look, A.T. Oncogenic transcription factors in the human acute leukemias. Science 278, 1059–1064 (1997).
Lin, R. J. & Evans, R.M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821–830 (2000).
Minucci, S., et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811–820 (2000).
Melnick, A. & Licht, J.D. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167–3215 (1999).
He, L.Z., Merghoub, T. & Pandolfi, P.P. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 18, 5278–5292 (1999).
Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940–954 (1996).
Pandolfi, P.P. et al. Structure and origin of the acute promyelocytic leukemia myl/RARα cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene 6, 1285–1292 (1991).
de Thé, H. et al. The PML/RARalpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66, 675–684 (1991).
Kakizuka, A. et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell 66, 663–674 (1991).
Grignani, F. et al. The acute promyelocytic leukemia specific PML/RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74, 423–431 (1993).
He, L.Z. et al. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nature Genet. 18, 126–135 (1997).
Lin, R.J. et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391, 811–814 (1998).
Grignani, F. et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815–818 (1998).
Zhong, S., Salomoni, P. & Pandolfi, P.P. The transcriptional role of PML and the nuclear body. Nature Cell Biol. 2, E85–E90 (2000).
Warrell, R.P. Jr., He, L.Z., Richon, V., Calleja, E. & Pandolfi, P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90, 1621–1625 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salomoni, P., Pandolfi, P. Transcriptional regulation of cellular transformation. Nat Med 6, 742–744 (2000). https://doi.org/10.1038/77459
Issue Date:
DOI: https://doi.org/10.1038/77459
This article is cited by
-
Role of PML and the PML-nuclear body in the control of programmed cell death
Oncogene (2003)
-
Functional inactivation of Cdk9 through oligomerization chain reaction
Oncogene (2003)
-
Transcription therapy for cancer
Oncogene (2001)
-
In vivo analysis of the molecular genetics of acute promyelocytic leukemia
Oncogene (2001)
